Articles
This Stream includes all of our Articles Flipbooks
-
Read FlipbookThe Right Way to Use Genetic Information in Clinical Trials
-
Read FlipbookQ&A with CNS Expert, Dr. Leslie Citrome
Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
-
Request a Genetics in Clinical Trials training session
What You'll Learn -
Read FlipbookQ&A with CNS Expert, Dr. Christoph U. Correll
Christoph U. Correll, MD, a member of WCG’s Scientific Leadership Team, shared his thoughts in a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
-
Read FlipbookTrend: Genetic Testing and Data Privacy Ownership
-
Read FlipbookAdverse Event Reporting: When TMI is Risky
-
Read FlipbookOptimizing Global Safety Reporting in Clinical Trials
-
Benchmark your study enrollment versus competitors
Get Benchmark Data -
Read FlipbookCNS Drugs Take Longer to Develop, Win Approval
CNS drugs take 20% longer to develop and about 19 months (36%) longer on average than other meds to win FDA approval after clinical trials
-
Read FlipbookMaster Protocols Can Kickstart Clinical Trials
-
Read FlipbookWCG, Inspire Team Up to Boost Trial Access
-
Read FlipbookAre Scientists Closing in on Treatments for Schizophrenia's Most Elusive Symptoms?
Researchers, buoyed by a spike in promising clinical trials and tools, believe they may be close to unraveling new ways to treat some of the most insidious yet elusive effects of schizophrenia
-
Read Flipbook
IRBs can make the most of central IRB partnerships
The IRB at Inova Health System of Falls Church, VA, began working with a central IRB 15 years ago. Since then, the IRB developed a well-organized process for its partnerships with independent IRBs.
-
Read FlipbookNavigation Through Fair Market Value Ambiguity
-
Read Flipbook
Conquer Study Start-Up Delays With a Data-Driven Approach
A new approach to solving start-up delays is built on this foundation of advanced data analytics and accelerates study start-up timelines by 33 percent.
-
Read FlipbookFDA Posts First List of Surrogate Endpoints
-
Read FlipbookGenetics in Precision Medicine: A Data Management Issue
-
Read Flipbook
Finding Good Sites in Today’s Competitive Site Landscape
-
Read FlipbookImproving Clinical Site Payment Practices
-
Read Flipbook
IRBs and IBCs: Critical Partners in Gene Research
-
Read FlipbookImproving Subject Selection and Endpoint Management in Alzheimer's Trials
-
Read FlipbookDMC Regulations May Change, but Principles Won't
-
Loading More...
